Shares of Apricus Biosciences Inc. plunged 70 percent Friday on word that the FDA issued another complete response letter (CRL) for the resubmitted new drug application (NDA) of Vitaros (alprostadil, DDAIP.HCl) to treat erectile dysfunction (ED). In late 2016, the San Diego-based company was hopeful that it had found a road forward in the U.S. for Vitaros – approved in Canada and in certain countries in Europe, Latin America and the Middle East – by resolving issues in the CRL dating back to 2008.